

# Mohammad Hossein Pourgholami

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2949701/publications.pdf>

Version: 2024-02-01

76  
papers

3,163  
citations

126708

33  
h-index

168136

53  
g-index

77  
all docs

77  
docs citations

77  
times ranked

4894  
citing authors

#	ARTICLE	IF	CITATIONS
1	Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 143-162.	2.7	171
2	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013, 4, 502-530.	0.8	152
3	In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. <i>Cancer Letters</i> , 2001, 165, 43-49.	3.2	121
4	Involvement of Urokinase-type Plasminogen Activator System in Cancer: An Overview. <i>Medicinal Research Reviews</i> , 2014, 34, 918-956.	5.0	117
5	Gene of the month: Interleukin 6 (IL-6). <i>Journal of Clinical Pathology</i> , 2014, 67, 932-937.	1.0	106
6	Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 4509.	1.5	104
7	Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 425-432.	1.1	95
8	Inhibition of the IL-6 signaling pathway: A strategy to combat chronic inflammatory diseases and cancer. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 163-173.	3.2	90
9	The fruit essential oil of <i>Pimpinella anisum</i> exerts anticonvulsant effects in mice. <i>Journal of Ethnopharmacology</i> , 1999, 66, 211-215.	2.0	89
10	Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice. <i>Clinical Cancer Research</i> , 2006, 12, 1928-1935.	3.2	86
11	Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. <i>Journal of Nanobiotechnology</i> , 2015, 13, 25.	4.2	86
12	Urokinase plasminogen activator system as a potential target for cancer therapy. <i>Future Oncology</i> , 2009, 5, 1487-1499.	1.1	84
13	Effect of Cross-Linking on the Performance of Micelles As Drug Delivery Carriers: A Cell Uptake Study. <i>Biomacromolecules</i> , 2012, 13, 814-825.	2.6	74
14	Diffuse malignant peritoneal mesothelioma – An update on treatment. <i>Cancer Treatment Reviews</i> , 2012, 38, 605-612.	3.4	71
15	p70 Ribosomal protein S6 kinase ( <i>Rps6kb1</i> ): an update. <i>Journal of Clinical Pathology</i> , 2014, 67, 1019-1025.	1.0	70
16	Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 597-605.	1.1	64
17	In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. <i>Cancer Letters</i> , 2000, 151, 97-102.	3.2	63
18	Evaluation of the anticonvulsant activity of the essential oil of <i>Eugenia caryophyllata</i> in male mice. <i>Journal of Ethnopharmacology</i> , 1999, 64, 167-171.	2.0	62

#	ARTICLE	IF	CITATIONS
19	Pilot Study of Albendazole in Patients with Advanced Malignancy. <i>Oncology</i> , 2001, 61, 42-46.	0.9	62
20	PEGylated Albumin-Based Polyion Complex Micelles for Protein Delivery. <i>Biomacromolecules</i> , 2016, 17, 808-817.	2.6	59
21	Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 729-734.	1.0	54
22	MUC1 as a Potential Target in Anticancer Therapies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 108-118.	0.6	54
23	Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. <i>Anticancer Research</i> , 2009, 29, 3791-6.	0.5	52
24	Potent inhibition of tumoral hypoxia-inducible factor 1 $\alpha$ by albendazole. <i>BMC Cancer</i> , 2010, 10, 143.	1.1	48
25	Neuroprotective effects of astaxanthin in a rat model of spinal cord injury. <i>Behavioural Brain Research</i> , 2017, 329, 104-110.	1.2	46
26	Enhanced cytotoxicity of benzimidazole carbamate derivatives and solubilisation by encapsulation in cucurbit[n]uril. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 3328.	1.5	45
27	Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. <i>Biochemical Pharmacology</i> , 2007, 74, 407-414.	2.0	44
28	Effect of shell-crosslinking of micelles on endocytosis and exocytosis: acceleration of exocytosis by crosslinking. <i>Biomaterials Science</i> , 2013, 1, 265-275.	2.6	43
29	Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. <i>Anticancer Research</i> , 2008, 28, 3757-61.	0.5	41
30	Triggering the fast release of drugs from crosslinked micelles in an acidic environment. <i>Journal of Materials Chemistry</i> , 2011, 21, 12777.	6.7	39
31	Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies. <i>PLoS ONE</i> , 2013, 8, e60817.	1.1	39
32	Evaluation of the anticonvulsant profile of progesterone in male amygdala-kindled rats. <i>Epilepsy Research</i> , 1998, 30, 195-202.	0.8	38
33	Inhibitors of Vascular Endothelial Growth Factor in Cancer. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2008, 6, 343-347.	0.4	34
34	An Optimized RGD-Decorated Micellar Drug Delivery System for Albendazole for the Treatment of Ovarian Cancer: From RAFT Polymer Synthesis to Cellular Uptake. <i>Macromolecular Bioscience</i> , 2011, 11, 219-233.	2.1	34
35	Minocycline inhibits growth of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 433-440.	0.6	34
36	Comparison of Shell-Cross-Linked Micelles with Soft and Glassy Cores as a Drug Delivery Vehicle for Albendazole: Is There a Difference in Performance?. <i>Macromolecules</i> , 2012, 45, 5451-5462.	2.2	32

#	ARTICLE	IF	CITATIONS
37	Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole. <i>Cancer Investigation</i> , 2009, 27, 171-177.	0.6	30
38	Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells. <i>Anticancer Research</i> , 2008, 28, 2775-9.	0.5	28
39	Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. <i>Cancer Letters</i> , 2011, 300, 122-133.	3.2	25
40	Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways. <i>Gynecologic Oncology</i> , 2013, 129, 113-119.	0.6	25
41	Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 388-394.	0.6	25
42	The acute effects of estradiol benzoate on amygdala-kindled seizures in male rats. <i>Brain Research</i> , 2001, 891, 1-6.	1.1	24
43	Effect of minocycline on pentylenetetrazol-induced chemical kindled seizures in mice. <i>Neurological Sciences</i> , 2014, 35, 571-576.	0.9	24
44	The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: a review study. <i>Nutrition and Cancer</i> , 2021, 73, 1-15.	0.9	24
45	Intra-amygdala infusion of 2-chloroadenosine suppresses amygdala-kindled seizures. <i>Brain Research</i> , 1997, 775, 37-42.	1.1	23
46	Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model. <i>PLoS ONE</i> , 2011, 6, e24405.	1.1	22
47	Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. <i>Cancer Treatment Reviews</i> , 2012, 38, 854-860.	3.4	22
48	Effect of intraperitoneal and intrahippocampal (CA1) 2-chloroadenosine in amygdaloid kindled rats. <i>Brain Research</i> , 1997, 751, 259-264.	1.1	20
49	1,25-Dihydroxyvitamin D3 induced cell cycle arrest in the human primary liver cancer cell line HepG2. <i>Hepatology Research</i> , 2003, 26, 34-39.	1.8	20
50	The role of ER $\alpha$ 36 in cell type-specific functions of estrogen and cancer development. <i>Pharmacological Research</i> , 2021, 163, 105307.	3.1	18
51	Minocycline attenuates hypoxia-inducible factor-1 $\alpha$ expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. <i>American Journal of Cancer Research</i> , 2015, 5, 575-88.	1.4	18
52	Intraperitoneal and intraamygdala N6-cyclohexyladenosine suppress hippocampal kindled seizures in rats. <i>Brain Research</i> , 2000, 858, 48-54.	1.1	17
53	Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 987-994.	1.2	17
54	Anticonvulsant action of 2-chloroadenosine injected focally into the perirhinal cortex in amygdaloid kindled rats. <i>Epilepsy Research</i> , 1999, 37, 37-43.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Novel protein interactors of urokinase-type plasminogen activator receptor. <i>Biochemical and Biophysical Research Communications</i> , 2010, 399, 738-743.	1.0	16
56	Albendazole loaded albumin nanoparticles for ovarian cancer therapy. <i>European Journal of Nanomedicine</i> , 2014, 6, .	0.6	16
57	Synthesis of semi-biodegradable crosslinked microspheres for the delivery of 1,25 dihydroxyvitamin D3 for the treatment of hepatocellular carcinoma. <i>European Polymer Journal</i> , 2007, 43, 1754-1767.	2.6	15
58	Expression patterns of ER $\alpha$ 66 and its novel variant isoform ER $\alpha$ 36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics. <i>Pituitary</i> , 2020, 23, 232-245.	1.6	15
59	Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod. <i>Frontiers in Pharmacology</i> , 2022, 13, 807639.	1.6	15
60	HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	14
61	Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells. <i>Tumor Biology</i> , 2014, 35, 5037-5048.	0.8	14
62	Initial Report on Differential Expression of Sprouty Proteins 1 and 2 in Human Epithelial Ovarian Cancer Cell Lines. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	12
63	Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol. <i>Cancer Letters</i> , 2004, 207, 37-47.	3.2	11
64	Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application. <i>Journal of Oncology</i> , 2012, 2012, 1-14.	0.6	11
65	Effects of chronic estradiol benzoate treatment on amygdala kindled seizures in male rats. <i>Epilepsy Research</i> , 2001, 46, 45-51.	0.8	10
66	Estradiol alters afterdischarge threshold and acquisition of amygdala kindled seizures in male rats. <i>Neuroscience Letters</i> , 2003, 340, 41-44.	1.0	10
67	MUC1 has Prognostic Significance in Malignant Peritoneal Mesothelioma. <i>International Journal of Biological Markers</i> , 2013, 28, 303-312.	0.7	10
68	Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. <i>Anticancer Research</i> , 2007, 27, 417-22.	0.5	10
69	Hepatic arterial and intravenous administration of 1,25-dihydroxyvitamin D 3 - evidence of a clinically significant hepatic first-pass effect. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 209-214.	1.1	9
70	Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. <i>American Journal of Cancer Research</i> , 2013, 3, 411-23.	1.4	7
71	Evidence for serotonergic system involvement in the effect of morphine on gastrointestinal motility in the rat. <i>General Pharmacology</i> , 1995, 26, 779-783.	0.7	6
72	The influence of ovarian cancer induced peritoneal carcinomatosis on the pharmacokinetics of albendazole in nude mice. <i>Anticancer Research</i> , 2010, 30, 423-8.	0.5	5

#	ARTICLE	IF	CITATIONS
73	Long-term Survival and Propensity Score Matched Outcomes of Bilateral vs. Unilateral Diaphragm Interventions in Cytoreductive Surgery plus Intra-peritoneal Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 5917-5921.	0.5	4
74	Anticancer properties of novel aminoacetonitrile derivative monepantel (ADD 1566) in pre-clinical models of human ovarian cancer. <i>American Journal of Cancer Research</i> , 2014, 4, 545-57.	1.4	4
75	Peritoneal mesothelioma in a woman who has survived for seven years: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 36.	0.4	3
76	Monepantel antitumor activity is mediated through inhibition of major cell cycle and tumor growth signaling pathways. <i>American Journal of Cancer Research</i> , 2021, 11, 3098-3110.	1.4	0